- Syncona said portfolio company Blue Earth Diagnostics had announced encouraging study results for a diagnostic solution for prostate cancer.

The results were from early clinical experience in an academic setting with a radiohybrid PSMA-targeted agent, rhPSMA-7 in high-risk primary and recurrent prostate cancer.

Blue Earth acquired rhPSMA-7 in 2018 to extend its position in prostate cancer imaging, including potential new areas of high unmet need, such as early stage primary prostate cancer patients.

The Technical University at Munich has utilised the agent in early clinical experience in men with both primary and recurrent cancer.

A retrospective analysis of 58 patients with high risk primary prostate cancer indicated that 18F-rhPSMA-7 PET/CT demonstrated sensitivity of 72%, specificity of 93% and diagnostic accuracy 86%, when compared to histopathological findings.

A retrospective analysis of 261 patients with biochemically recurrent prostate cancer in which 18F-rhPSMA-7 PET/CT demonstrated a detection rate of 81% at a median PSA level of 0.96 ng/mL.

'We are encouraged by these results, which provide further evidence to support the potential clinical utility of rhPSMA-7 in both high-risk primary and recurrent prostate cancer,' Sycona Investments chief executive Martin Murphy said.

'While Blue Earth will next look to test this hypothesis in its own clinical trial, this data reinforces our belief that this PSMA agent is one of the leading assets in the space and should enable Blue Earth to extend its leading position in prostate cancer diagnostics.'

Story provided by